Doxorubicin and Trastuzumab interaction

Doxorubicin and Trastuzumab: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Doxorubicin (Doxorubicin Hydrochloride) label · effective 2026-05-05

Major

• Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction ( 5.1 , 7.2 )

Drug interactionsnames TrastuzumabView label on DailyMed
Major

Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab [see Warnings and Precautions (5.1) ].

Drug interactionsnames TrastuzumabView label on DailyMed
Major

Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible.

Drug interactionsnames TrastuzumabView label on DailyMed
Moderate

There is an additive or potentially synergistic increase in the risk of cardiomyopathy in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab.

Warnings and precautionsnames TrastuzumabView label on DailyMed
Moderate

Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction.

Drug interactionsnames TrastuzumabView label on DailyMed

From the Trastuzumab (Trazimera) label · effective 2026-04-10

Major

AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology.

Warnings and precautionsnames DoxorubicinView label on DailyMed
Moderate

Table 2: Incidence of Cardiac Dysfunction Congestive heart failure or significant asymptomatic decrease in LVEF. in Metastatic Breast Cancer Studies Incidence NYHA I–IV NYHA III–IV Study Event Trastuzumab Control Trastuzumab Control H0648g (AC) Anthracycline (doxorubicin or epirubicin) and cyclophosphamide.

Warnings and precautionsnames DoxorubicinView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.